Novartis’ Pluvicto Demonstrates Positive Phase III Results in mCRPC Treatment
Swiss pharmaceutical giant Novartis (NYSE: NVS) has released encouraging data from a Phase III study...
Clinical trial results
Dizal’s Sunvozertinib Shows Promising Efficacy in Advanced NSCLC at ESMO 2023
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) presented compelling efficacy and safety data for its...
Shandong Luoxin’s LX-039 Demonstrates Promise in Phase I Oncology Study at ESMO
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd (SHE: 002793), a China-based pharmaceutical innovator, has published...
Kintor’s Proxalutamide Shows Promise in Metastatic Breast Cancer Study at ESMO
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has published the latest data from a Phase Ic...
Ascentage Pharma’s Pelcitoclax Shows Promise in ESMO Study for NSCLC
Suzhou-based pharmaceutical company Ascentage Pharma (HKG: 6855) has published the latest results from a Phase...
Transcenta Holdings Unveils Updated Osemitamab Data in Advanced Gastric Cancer at ESMO
China-based biotech Transcenta Holdings Ltd (HKG: 6628) has presented updated efficacy data from the expansion...
Alphamab Oncology Presents Promising Data for KN046 and KN026 at ESMO 2023
China-based Alphamab Oncology (HKG: 9966) has released data snapshots from clinical studies for two of...
Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...
Novartis’ Kisqali Plus Endocrine Therapy Shows Improved Survival in Early Breast Cancer Study
Switzerland-based pharmaceutical company Novartis (NYSE: NVS) has announced additional results from an ongoing Phase III...
Jacobio Pharma’s Glecirasib Combo Shows Promising Results in ESMO Congress 2023 Presentation
China-based Jacobio Pharma (HKG: 1167) has presented clinical data for its KRAS G12C inhibitor glecirasib...
InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023
China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...
BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...
Qilu Pharmaceutical Presents Promising Data for QL1706 and QL1209 at ESMO 2023
China-based Qilu Pharmaceutical has announced the presentation of clinical data for two of its pipeline...
Roche’s Alecensa Shows Unprecedented 76% Improvement in Disease-Free Survival in NSCLC Trial
Roche (SWX: ROG) subsidiary Genentech has revealed preliminary but promising results from a Phase III...
BeiGene’s Tislelizumab Shows Promising Results in ESMO Presentations for GC/GEJC and NSCLC
China-based biotech BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced two late-breaking presentations...
Mabwell to Present Promising Clinical Data at 2023 ESMO Congress
China-based Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it will present the...
Eli Lilly’s Tirzepatide Shows Robust Weight Loss Results in Phase III Study
Eli Lilly (NYSE: LLY) has released compelling efficacy results from a Phase III study evaluating...
Abbisko Therapeutics to Unveil Phase I Data for ABSK011 and ABSK043 at ESMO 2023
Shanghai-based biotech powerhouse Abbisko Therapeutics Co., Ltd (HKG: 2256) is preparing to present the results...
Kelun-Biotech to Present SKB264 Study Results for Metastatic Breast Cancer at ESMO
China-based pharmaceutical innovator Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) and its subsidiary Sichuan Kelun-Biotech...
Roche’s Ocrevus Demonstrates Long-Term Efficacy in Multiple Sclerosis Treatment
Swiss pharmaceutical giant Roche (SWX: ROG) has presented compelling long-term efficacy data for its selective...